My Diabetes Care for Diabetes Mellitus, Type 2

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Brigham and Women's Hospital, Boston, MA
Diabetes Mellitus, Type 2+1 More
My Diabetes Care - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to conduct a two-arm, parallel-design, pragmatic randomized controlled trial of a patient portal intervention for diabetes, My Diabetes Care (MDC), to evaluate its effect on clinical outcomes.

Eligible Conditions

  • Diabetes Mellitus, Type 2

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Change in Blood Glucose Control
Change in Blood Pressure Control
Change in Body Mass Index (BMI)
Change in Diabetes Self-Care (Diabetes Medication Adherence)
Change in Diabetes Self-Care (Exercise Adherence)
Change in Diabetes Self-Care (General Diet Adherence)
Change in Diabetes Self-Care (Self-Monitoring of Blood Glucose Adherence)
Change in Low Density Lipoprotein (LDL)
Satisfaction/Usability of My Diabetes Care (for Intervention Group)
Urine Albumin-to-Creatinine Ratio
Usability of MyChart (for Control Group)

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Usual Care
1 of 2
My Diabetes Care
1 of 2
Active Control
Experimental Treatment

484 Total Participants · 2 Treatment Groups

Primary Treatment: My Diabetes Care · No Placebo Group · N/A

My Diabetes Care
Other
Experimental Group · 1 Intervention: My Diabetes Care · Intervention Types: Other
Usual CareNoIntervention Group · 1 Intervention: Usual Care · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline (t0), three-month follow-up (t1), six-month follow-up (t2), twelve-month follow-up (t3)
Closest Location: Brigham and Women's Hospital · Boston, MA
Photo of Boston 1Photo of Boston 2Photo of Boston 3
2008First Recorded Clinical Trial
27 TrialsResearching Diabetes Mellitus, Type 2
1051 CompletedClinical Trials

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,390 Previous Clinical Trials
24,521,073 Total Patients Enrolled
35 Trials studying Diabetes Mellitus, Type 2
4,799 Patients Enrolled for Diabetes Mellitus, Type 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,094 Previous Clinical Trials
5,051,009 Total Patients Enrolled
200 Trials studying Diabetes Mellitus, Type 2
1,171,687 Patients Enrolled for Diabetes Mellitus, Type 2
Vanderbilt University Medical CenterLead Sponsor
758 Previous Clinical Trials
589,603 Total Patients Enrolled
11 Trials studying Diabetes Mellitus, Type 2
1,988 Patients Enrolled for Diabetes Mellitus, Type 2
William Martinez, MD, MSPrincipal InvestigatorVanderbilt University Medical Center
6 Previous Clinical Trials
1,070 Total Patients Enrolled
4 Trials studying Diabetes Mellitus, Type 2
510 Patients Enrolled for Diabetes Mellitus, Type 2

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have type 2 diabetes.\n
You are a patient at Vanderbilt University Medical Center or Brigham and Women's Hospital.
You are an active patient at Vanderbilt University Medical Center.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.